News|Videos|November 7, 2023

Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

Author(s)Sagar Lonial, MD, FACP, FASCO, Luciano Costa, MD, PhD, Cesar Rodriguez, MD

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Episodes in this series

Experts on multiple myeloma

EP. 1 Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma

Experts on multiple myeloma

EP. 2 Earlier Use of Novel Therapeutics in Multiple Myeloma Treatment Pathways

Experts on MM

EP. 3 Patient Scenario: Management of Multiple Myeloma With Talquetamab Therapy

Experts on MM

EP. 4 Bispecific Therapies in RRMM: Teclistamab, Talquetamab, and Elranatamab Updates

Experts on MM

EP. 5 Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice

Experts on MM

EP. 6 Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes

Experts on MM

EP. 7 Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies

EP. 8 Multiple Myeloma: Optimizing ICANS and CRS Management

EP. 8 Multiple Myeloma: Optimizing ICANS and CRS Management

$A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.$

EP. 9 Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

Experts on MM

EP. 10 Patient Scenario: Navigating Sequencing in Multiple Myeloma

Experts on MM

EP. 11 CAR-T vs BCMA Bispecifics: Navigating Myeloma Treatment Decisions

Experts on MM

EP. 12 Navigating CAR-T Therapy in RRMM: Patient Counsel and Managing AEs

EP. 13 Advancements in Multiple Myeloma IO Therapy: Key Takeaways

EP. 13 Advancements in Multiple Myeloma IO Therapy: Key Takeaways

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

November 4th, 2026

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

Trending on CancerNetwork

Building Systems to Catch Liver and Other Cancers in Patients With MASLD

Closing the HCC Surveillance Gap in MASLD Without Cirrhosis

Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC

Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis

Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses